|
Prospective model of PPARA variants and non-fatal myocardial infarction risk in the Go-DARTs cohort. A full set of data was available on 1806 individuals, 108 recorded non fatal myocardial infarctions during the period of observation, with a total of 94497.6 months of observation. Both PPARA variants were analysed using a co-dominant model. |
|||
| Hazard Ratio |
95% CI |
P |
|
|
|
|||
| V162 |
0.31 |
0.10 0.93 |
0.037 |
| C2528 |
2.77 |
1.34 5.75 |
0.006 |
| Smoking |
1.39 |
0.93 2.10 |
0.112 |
| Gender |
0.72 |
0.48 1.08 |
0.107 |
| Age at recruitment |
1.05 |
1.02 1.07 |
<0.001 |
| Insulin treatment |
2.56 |
1.69 3.89 |
<0.001 |
| Prevalent angina |
5.64 |
3.80 8.40 |
<0.001 |
| Prevalent cerebrovascular disease |
1.29 |
0.67 2.51 |
0.445 |
| Prevalent myocardial infarction |
3.90 |
2.60 5.81 |
<0.001 |
| Haplotypes |
|||
| L162-G2582 |
Ref |
||
| L162-C2528 |
1.68 |
1.16–2.43 |
0.006 |
| V162-G2528 |
0.54 |
0.20–1.48 |
0.23 |
| V162-C2528 |
0.96 |
0.48–1.94 |
0.91 |
Doney et al. Nuclear Receptor 2005 3:4 doi:10.1186/1478-1336-3-4 |
|||